Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.

In the present trial, we compared the broncholytic efficacy of the combination therapy with 50 microg salmeterol + 250 microg fluticasone and 12 microg formoterol + 400 microg budesonide, both in a single inhaler device, in 16 patients with moderate-to-severe COPD. The study was performed using a single-blind crossover randomized study. Lung function, pulse oximetry (SpO2) and heart rate were monitored before and 15, 30, 60, 120, 180, 240, 300, 360, 480, 600, and 720 min after bronchodilator inhalation. Both combinations were effective in reducing airflow obstruction. FEV1 AUC(0-12 h) was 2.83 l (95% CI: 2.13-3.54) after salmeterol/fluticasone and 2.57 l (95% CI: 1.97-3.2) after formoterol/budesonide. Formoterol/budesonide elicited the mean maximum improvement in FEV1 above baseline after 120 min (0.29 l; 95% CI: 0.21-0.37) and salmeterol/fluticasone after 300 min (0.32 l; 95% CI: 0.23-0.41). At 720 min, the increase in FEV1 over baseline values was 0.10 l (95% CI: 0.07-0.12) after salmeterol/fluticasone and 0.10 l (95% CI: 0.07-0.13) after formoterol/budesonide. The mean peak increase in heart rate occurred 300 min after formoterol/budesonide (1.5 b/min; 95% CI--2.3 to 5.3) and 360 min after salmeterol/fluticasone (2.6 b/min; 95% CI--1.9 to 7.0). SpO2 did not change. All differences between salmeterol/fluticasone and formoterol/budesonide were not significant (P > 0.05) except those in FEV1 at 120 and 360 min. The results indicate that an inhaled combination therapy with a long-acting beta2-agonist and an inhaled corticosteroid appears to be effective in improving airway limitation after acute administration in patients suffering from COPD.

[1]  N. Pride,et al.  Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice , 2002, European Respiratory Journal.

[2]  Abdullah Alsaeedi,et al.  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. , 2002, The American journal of medicine.

[3]  R. Pauwels.  Inhaled glucocorticosteroids and chronic obstructive pulmonary disease: how full is the glass? , 2002, American journal of respiratory and critical care medicine.

[4]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[5]  J. Lötvall,et al.  Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. , 2001, Pulmonary pharmacology & therapeutics.

[6]  M. Cazzola,et al.  Additive effects of salmeterol and fluticasone or theophylline in COPD. , 2000, Chest.

[7]  S. Nava,et al.  Controlled short-term trial of fluticasone propionate in ventilator-dependent patients with COPD. , 2000, Chest.

[8]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[9]  P. Barnes,et al.  Up-Regulation of Airway Smooth Muscle Histamine H 1 Receptor mRNA , Protein , and Function by b 2-Adrenoceptor Activation , 2000 .

[10]  A. Knox,et al.  Synergistic Inhibition by β2-Agonists and Corticosteroids on Tumor Necrosis Factor- α –Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells , 2000 .

[11]  M. Cazzola,et al.  Non-Pulmonary Effects Induced by the Addition of Formoterol to Budesonide Therapy in Patients with Mild or Moderate Persistent Asthma , 2000, Respiration.

[12]  O. Kayacan,et al.  Formoterol and Salmeterol in Partially Reversible Chronic Obstructive Pulmonary Disease: A Crossover, Placebo-Controlled Comparison of Onset and Duration of Action , 1999, Respiration.

[13]  L. Edwards,et al.  Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. , 1999, Chest.

[14]  B. Lipworth,et al.  Concomitant inhaled corticosteroid resensitises cardiac β2-adrenoceptors in the presence of long-acting β2-agonist therapy , 1998, European Journal of Clinical Pharmacology.

[15]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[16]  M. Cazzola,et al.  The use of bronchodilators in stable chronic obstructive pulmonary disease. , 1997, Pulmonary pharmacology & therapeutics.

[17]  R. Belshe.  A review of attenuation of influenza viruses by genetic manipulation. , 1995, American journal of respiratory and critical care medicine.

[18]  M. Cazzola,et al.  Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. , 1995, Respiratory medicine.

[19]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.